EASD 2025
15 - 19 September 2025
REDEFINE 2: A randomised trial of combined semaglutide 2.4 mg and cagrilintide 2.4 mg for the treatment of adults with BMI ≥27 kg/m2 and type 2 diabetes
Keywords
Get notified when materials for EASD 2025 and future congresses become available:
Get notified when materials for EASD 2025 and future congresses become available:
Success
We will notify you when new materials become available for EASD 2025 and future congresses.
We will keep you updated in your inbox:
Almost Done